Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$8.68
-4.0%
$10.66
$6.72
▼
$17.78
$379.70M1.07562,296 shs369,212 shs
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
$2.96
-11.4%
$3.66
$2.80
▼
$32.13
$120.03M0.781.23 million shs951,262 shs
Oculis Holding AG stock logo
OCS
Oculis
$7.06
-5.1%
$8.33
$6.78
▼
$34.47
$442.42M0.67309,876 shs235,175 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$2.21
-5.8%
$2.46
$1.23
▼
$3.11
$452.96M0.242.69 million shs2.83 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-2.16%-7.57%+6.86%-47.41%-27.27%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
+3.52%-18.75%+4.17%-29.00%-88.30%
Oculis Holding AG stock logo
OCS
Oculis
+0.68%-0.80%-0.67%-43.16%-61.39%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
+3.54%-8.24%-0.85%-16.43%+82.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$8.68
-4.0%
$10.66
$6.72
▼
$17.78
$379.70M1.07562,296 shs369,212 shs
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
$2.96
-11.4%
$3.66
$2.80
▼
$32.13
$120.03M0.781.23 million shs951,262 shs
Oculis Holding AG stock logo
OCS
Oculis
$7.06
-5.1%
$8.33
$6.78
▼
$34.47
$442.42M0.67309,876 shs235,175 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$2.21
-5.8%
$2.46
$1.23
▼
$3.11
$452.96M0.242.69 million shs2.83 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-2.16%-7.57%+6.86%-47.41%-27.27%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
+3.52%-18.75%+4.17%-29.00%-88.30%
Oculis Holding AG stock logo
OCS
Oculis
+0.68%-0.80%-0.67%-43.16%-61.39%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
+3.54%-8.24%-0.85%-16.43%+82.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
2.20
Hold$21.40146.54% Upside
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
2.43
Hold$14.75398.31% Upside
Oculis Holding AG stock logo
OCS
Oculis
2.75
Moderate Buy$38.57446.34% Upside
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
2.83
Moderate Buy$6.13177.78% Upside

Current Analyst Ratings Breakdown

Latest LENZ, OCS, OVID, and CTNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Oculis Holding AG stock logo
OCS
Oculis
Reiterated RatingBuy$39.00
11/5/2026
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
Lower Price TargetBuy$10.00 ➝ $9.00
11/4/2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Set Price Target$23.00
11/4/2026
Oculis Holding AG stock logo
OCS
Oculis
Lower Price TargetBuy$40.00
10/30/2026
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
Lower Price TargetBuy$16.00
10/21/2026
Oculis Holding AG stock logo
OCS
Oculis
Reiterated RatingBuy$39.00
10/19/2026
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
Lower Price TargetNeutral$7.00 ➝ $5.00
10/19/2026
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
Lower Price TargetNeutral$7.00 ➝ $5.00
10/15/2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Reiterated RatingSell (D-)
10/15/2026
Oculis Holding AG stock logo
OCS
Oculis
Reiterated RatingSell (D-)
10/15/2026
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
Reiterated RatingSell (D-)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$50M6.82N/AN/A$6.25 per share1.39
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
$19.09M4.87N/AN/A$6.11 per share0.48
Oculis Holding AG stock logo
OCS
Oculis
$1.45M282.30N/AN/A$4.43 per share1.59
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$7.25M57.40N/AN/A$1.05 per share2.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$59.98M-$1.77N/AN/AN/AN/A-25.48%-24.28%N/A
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$82.13M-$4.49N/AN/AN/A-1,134.97%-59.56%-54.75%N/A
Oculis Holding AG stock logo
OCS
Oculis
-$119.44M-$1.71N/AN/AN/A-8,613.92%-39.24%-33.45%N/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$17.41M-$0.24N/AN/AN/AN/A-23.38%-20.76%N/A

Latest LENZ, OCS, OVID, and CTNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$0.0848-$0.10-$0.0153-$0.10$0.03 millionN/A
11/3/2026Q3 2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.4538-$0.49-$0.0363-$0.49$5.65 millionN/A
11/3/2026Q3 2026
Oculis Holding AG stock logo
OCS
Oculis
-$0.4713-$0.37+$0.1013-$0.36$0.26 million$0.01 million
10/28/2026Q3 2026
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$0.8932-$0.99-$0.0968-$0.99$4.20 million$3.38 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/AN/A
Oculis Holding AG stock logo
OCS
Oculis
N/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
31.11
31.11
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/A
11.66
11.39
Oculis Holding AG stock logo
OCS
Oculis
0.01
10.41
10.41
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.05
11.97
11.97

Institutional Ownership

CompanyInstitutional Ownership
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
54.32%
Oculis Holding AG stock logo
OCS
Oculis
22.30%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
72.24%

Insider Ownership

CompanyInsider Ownership
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
7.90%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
8.30%
Oculis Holding AG stock logo
OCS
Oculis
N/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
5139.27 million36.16 millionOptionable
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
15231.42 million28.81 millionOptionable
Oculis Holding AG stock logo
OCS
Oculis
6057.98 millionN/AOptionable
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
23188.73 million175.52 millionOptionable

Recent News About These Companies

Ovid Therapeutics GAAP EPS of -$0.10 misses by $0.02
Guggenheim Initiates Ovid Therapeutics at Buy
Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$8.68 -0.36 (-3.98%)
Closing price 04:00 PM Eastern
Extended Trading
$8.68 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

LENZ Therapeutics stock logo

LENZ Therapeutics NASDAQ:LENZ

$2.96 -0.38 (-11.38%)
Closing price 04:00 PM Eastern
Extended Trading
$2.96 +0.00 (+0.17%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Oculis stock logo

Oculis NASDAQ:OCS

$7.06 -0.38 (-5.11%)
Closing price 04:00 PM Eastern
Extended Trading
$7.06 0.00 (-0.07%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Ovid Therapeutics stock logo

Ovid Therapeutics NASDAQ:OVID

$2.20 -0.14 (-5.77%)
Closing price 03:59 PM Eastern
Extended Trading
$2.24 +0.03 (+1.36%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.